A011000 Stock Overview
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
GeneOne Life Science, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩2,695.00 |
52 Week High | ₩7,100.00 |
52 Week Low | ₩2,260.00 |
Beta | -1.87 |
1 Month Change | 6.73% |
3 Month Change | -5.11% |
1 Year Change | -57.89% |
3 Year Change | -65.45% |
5 Year Change | -11.83% |
Change since IPO | 220.32% |
Recent News & Updates
Shareholder Returns
A011000 | KR Biotechs | KR Market | |
---|---|---|---|
7D | 4.3% | 3.1% | 3.8% |
1Y | -57.9% | 23.4% | 13.0% |
Return vs Industry: A011000 underperformed the KR Biotechs industry which returned 23.4% over the past year.
Return vs Market: A011000 underperformed the KR Market which returned 13% over the past year.
Price Volatility
A011000 volatility | |
---|---|
A011000 Average Weekly Movement | 7.9% |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 5.3% |
10% most volatile stocks in KR Market | 12.0% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A011000 has not had significant price volatility in the past 3 months.
Volatility Over Time: A011000's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1976 | 75 | Young-Keun Park | https://www.genels.com |
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA under phase 2 stage for the treatment of SARS-CoV-2; GLS-5100 under pre-clinical stage for prevention of herpes zoster; and GLS-5140 under pre-clinical stage for the treatment of SFTS prophylaxis.
GeneOne Life Science, Inc. Fundamentals Summary
A011000 fundamental statistics | |
---|---|
Market cap | ₩217.97b |
Earnings (TTM) | -₩52.62b |
Revenue (TTM) | ₩37.29b |
5.7x
P/S Ratio-4.0x
P/E RatioIs A011000 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A011000 income statement (TTM) | |
---|---|
Revenue | ₩37.29b |
Cost of Revenue | ₩46.60b |
Gross Profit | -₩9.30b |
Other Expenses | ₩43.31b |
Earnings | -₩52.62b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -672.30 |
Gross Margin | -24.94% |
Net Profit Margin | -141.09% |
Debt/Equity Ratio | 2.0% |
How did A011000 perform over the long term?
See historical performance and comparison